Sabrina Sacconi, EAN 2023: The MycarinG study – rozanolixizumab in the treatment of muscle-specific kinase autoantibody-positive myasthenia gravis

Muscle-specific kinase autoantibody-positive (MuSK-Ab+) generalised myasthenia gravis (gMG) is usually more clinically severe than acetylcholine receptor autoantibody-positive (AChR-Ab+) gMG. The Phase 3 MycarinG study analysed rozanolixizumab in patients with AChR-Ab+ or MuSKAb+ gMG. Dr Sabrina Sacconi (Côte d’Azur University, Nice, France) summarizes the take-home messages from her presentation of the results of the study.

The abstract ‘EPO-391 Rozanolixizumab in muscle-specific kinase autoantibody-positive myasthenia gravis: Further analyses from MycarinG study’ was presented at the annual European Academy of Neurology (EAN), July 1–4, 2023

Questions

1. What are the current treatment options for muscle-specific kinase autoantibody-positive myasthenia gravis? (00:14)
2. What were the aims and rationale of the MycarinG study? (00:46)
3. What was the study design and methodology? (01:10)
4. Please can you summarize the key findings from the study? (01:45)
5. What conclusions can be made, and how might this impact future clinical practice? (02:25)

Disclosures: Sabrina Sacconi is a consultant for Dyne therapeutics and Sanofi. She has received grant/research support from Roche, Biogen and Lupin, and is a member of the advisory board for UCB pharma, Sanofi, Fulcrum, Alexion and Roche.

Support: Interview and filming was supported by Touch Medical Media. The interview was conducted by Sophie Nickelson.

Filmed as highlight of EAN 2023.